Delisting risk
Citius Oncology
Commercializing LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma.
$0.7756
After-hours close−0.01 (−1.50%)
At close$0.7874(−0.37%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Aug 2026 | −$0.07 | −$0.08 | −14.3% |
| May 2026 | −$0.01 | −$0.27 | −2,600.0% |
| Feb 2026 | −$0.04 | −$0.06 | −50.0% |
| Dec 2025 | −$0.06 | −$0.06 | 0.0% |
The latest year is open to everyone — the 13 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Dec 2024 | |||
| Mar 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Apr 2021 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | −$0.07 | −$0.08 | −14.3% | $2.5M | $1.5M | −40.2% |
| May 15, 2026 | −$0.01 | −$0.27 | −2,600.0% | $7.0M | $1.7M | −76.2% |
| Feb 13, 2026 | −$0.04 | −$0.06 | −50.0% | $4.4M | $3.9M | −9.8% |
| Dec 23, 2025 | −$0.06 | −$0.06 | 0.0% | — | — | — |
The latest year is open to everyone — the 13 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 14, 2025 | ||||||
| Feb 14, 2025 | ||||||
| Dec 27, 2024 | ||||||
| Mar 31, 2024 | ||||||
| Dec 31, 2023 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||
| Dec 31, 2022 | ||||||
| Sep 30, 2022 | ||||||
| Jun 30, 2022 | ||||||
| Apr 30, 2021 | ||||||